Nexpovio 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0016 
Minor change in labelling or package leaflet not 
14/08/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0014 
C.I.11.z - Introduction of, or change(s) to, the 
03/07/2023 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
IAIN/0013 
B.II.b.1.a - Replacement or addition of a 
19/04/2023 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
PSUSA/10926
Periodic Safety Update EU Single assessment - 
14/04/2023 
n/a 
PRAC Recommendation - maintenance 
/202209 
selinexor 
II/0011 
Update of section 4.5 of the SmPC in order to add 
26/01/2023 
SmPC 
Not applicable 
drug-drug interaction information regarding the 
strong CYP3A4 inhibitor, clarithromycin, based on 
results from the drug-drug interaction (DDI) 
pharmacokinetic (PK) portion of Study KCP 330-017 
(STOMP) following procedure 
EMEA/H/C/005127/REC/003.1. This is a Phase 1b/2, 
multi-center, open-label, clinical study with Dose 
Escalation (Phase 1) and Expansion (Phase 2) to 
independently assess the MTD, efficacy, and safety 
of 10 combination therapies in 11 arms in patients 
with RRMM (Relapsed/Refractory Multiple Myeloma) 
and NDMM (Newly Diagnosed Multiple Myeloma). 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IAIN/0010/G 
This was an application for a group of variations. 
11/11/2022 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
PSUSA/10926
Periodic Safety Update EU Single assessment - 
27/10/2022 
n/a 
PRAC Recommendation - maintenance 
/202203 
selinexor 
IAIN/0009/G 
This was an application for a group of variations. 
22/09/2022 
Annex II and 
PL 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0007 
Transfer of Marketing Authorisation 
24/06/2022 
22/07/2022 
SmPC, 
Labelling and 
PL 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0001/G 
This was an application for a group of variations. 
19/05/2022 
18/07/2022 
SmPC, Annex 
Please refer to Scientific Discussion ‘Nexpovio-H-C-5127-II-
II, Labelling 
0001/G’ 
and PL 
• 
Extension of indication for Nexpovio in 
combination with bortezomib and dexamethasone for 
the treatment of adult patients with multiple 
myeloma who have received at least one prior 
therapy and, 
• 
Addition of a new pack size (8 tablets) to 
align with the dose modification guidance for the new 
indication.  
Accordingly, Sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 
6.5 of the SmPC are updated to reflect the new 
indication and the new pack size.  
• 
Fulfilment of the Specific Obligation agreed 
in the context of the CMA of Nexpovio via the 
submission of results from the confirmatory Phase 3 
study, KCP-330-023, thereby supporting the granting 
of a marketing authorisation not subject to specific 
obligations. Annex II is updated to reflect the 
completion of the Specific Obligation. The Labelling 
and Package Leaflet are amended accordingly. The 
RMP (v 2.0) is amended consequently. 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
B.II.z - Quality change - Finished product - Other 
variation 
IB/0006/G 
This was an application for a group of variations. 
25/05/2022 
22/07/2022 
SmPC and PL 
C.I.z - To update the PL to include the name and address of 
the site responsible for batch release of the finished 
Page 4/7 
 
 
 
 
 
 
 
 
 
product.  
B.II.f.1.b.1 - To extend the shelf-life of the finished product 
as packaged for sale from 48 months to 60 months. 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.b.2.z - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
variation 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
R/0005 
Renewal of the marketing authorisation. 
24/03/2022 
13/05/2022 
Positive Opinion adopted by consensus together with the 
CHMP assessment report ‹and translation timetable›. 
The CHMP was of the opinion that the renewal for this 
conditional Marketing Authorisation can be granted. 
The Marketing Authorisation remains conditional. 
The Icelandic and Norwegian CHMP Members were in 
agreement with the CHMP Opinion. 
PSUSA/10926
Periodic Safety Update EU Single assessment - 
05/05/2022 
n/a 
PRAC Recommendation - maintenance 
/202109 
selinexor 
IA/0003/G 
This was an application for a group of variations. 
16/11/2021 
n/a 
B.I.b.2.c - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
changes to a test procedure for a reagent, which 
does not have a significant effect on the overall 
quality of the AS 
B.II.b.5.a - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
A.z - Administrative change - Other variation 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0002/G 
This was an application for a group of variations. 
10/09/2021 
13/05/2022 
SmPC 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.I.c.z - Container closure system of the AS - Other 
variation 
B.I.b.z - Change in control of the AS - Other 
variation 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
Page 6/7 
 
 
 
 
 
 
 
 
(supported by real time data) 
Page 7/7 
 
 
 
 
 
 
 
